OpportunityTitle: New Therapeutic Strategies for Genital Herpes (R21/R33 Clinical Trial Not Allowed)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Description: The purpose of this notice of funding opportunity (NOFO) is to stimulate the development of new treatments for genital herpes that suppress shedding and lesion formation and reduce transmission. This NOFO invites applications that propose research into a broad range of therapeutic approaches, including but not limited to development of new or improved antivirals, monoclonal antibodies, therapeutic vaccines, and gene editing technologies for treatment of patients living with genital herpes. This NOFO will use a milestone-driven, biphasic award mechanism. Transition to the second phase is not guaranteed and will depend on the successful completion of milestones.
GrantorContactEmailDescription: See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
GrantorContactText: NIH Grants Information&lt;br/&gt;grantsinfo@nih.gov